Technology | May 21, 2018

Innovative Health Receives FDA Clearance to Reprocess the ViewFlex Xtra Diagnostic Ultrasound Catheter

Company reprocesses devices with more complex technology, addressing the unmet need

The Abbott ViewFlex Xtra Diagnostic Ultrasound Catheter now can be reprocessed by Innovative Health.

May 21, 2018 — Cardiology medical device reprocessing company Innovative Health recently received U.S. Food and Drug Administration (FDA) clearance to reprocess the Abbott ViewFlex Xtra Diagnostic Ultrasound Catheter. Ultimately, this clearance will allow the company to develop a full product suite for clinicians based on this new category of devices, including other widely used mapping and imaging catheters.

The company said it launched this product reprocessing effort based on direct feedback from its customers, including clinicians in the electrophysiology (EP) field.The device is much more complex to reprocess than many types of catheters, which required the FDA clearance. 

Innovative Health continues to make extensive investments in research and development, enabling the company to pursue clearances for devices which are based on the very latest, difficult-to-reprocess technologies. In the last two years, the company has received three times more EP FDA clearances than all of its competitors combined. Reprocessors must actively pursue FDA clearances in order to introduce new products, which involves documenting that they can achieve levels of quality and safety comparable to those of the original device. This research can also help companies like Innovative Health identify entirely new reprocessing approaches, as it has with the ViewFlex catheter, allowing them to more easily pursue clearances for other new products based on similar technologies.

The ViewFlex catheter is used frequently in EP labs today to help visualize cardiac anatomy and physiology. With this recent FDA clearance, it will be added to Innovative Health’s vast portfolio of reprocessed devices include diagnostic, ultrasound and mapping catheters, as well as other EP-specific devices. Innovative Health partners with hospitals to collect the devices, then applies a rigorous, proprietary process to clean, test and sterilize them for re-use. As a result, the company claims it can help hospitals save hundreds of thousands of dollars on medical device spending per year, all while maintaining patient safety.

For more information: innovative-health.com

 

Related Content

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018
News | EP Lab | May 18, 2018
May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have under
Novel Antibiotics Can Help Lower EP Device Infection Rates. Pictured here is an ICD. Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

News | EP Lab | May 17, 2018
May 10, 2018 – A new study is the first to test the clinical effectiveness of incremental peri-operative antibiotics
The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT). #HRS2018

The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT).  

News | EP Lab | May 16, 2018
May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced
LivaNova Completes Sale of Cardiac Rhythm Management (CRM - electrophysiology) Business to MicroPort Scientific
News | EP Lab | April 30, 2018
April 30, 2018 — LivaNova announced it completed the sale of its cardiac rhythm management (CRM) business to MicroPor
LivaNova Enters Binding Letter of Intent to Sell Cardiac Rhythm Management Business
News | EP Lab | January 26, 2018
January 26, 2018 — LivaNova PLC and MicroPort Scientific Corp.
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab | October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab | October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab | September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Overlay Init